The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Long-acting Anti-HIV Drug Market Research Report 2025

Global Long-acting Anti-HIV Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1933189

No of Pages : 77

Ask Your Query
Synopsis
The global Long-acting Anti-HIV Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Long-acting anti-HIV drugs provide effective treatment options for HIV-infected people and have been widely recognized by the market. With the continuous deepening of research and development and the growth of market demand, long-acting anti-HIV drugs are expected to play a greater role in the future.
This report aims to provide a comprehensive presentation of the global market for Long-acting Anti-HIV Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Anti-HIV Drug.
Report Scope
The Long-acting Anti-HIV Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-acting Anti-HIV Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Anti-HIV Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
ViiV Healthcare
Janssen
Tibotec
Cipla
Frontier Biopharmaceutical (Nanjing) Co., Ltd.
Segment by Type
CAB Long-acting Injection
RPV Long-acting Injection
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long-acting Anti-HIV Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long-acting Anti-HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Long-acting Anti-HIV Drug Market Overview
1.1 Product Overview and Scope of Long-acting Anti-HIV Drug
1.2 Long-acting Anti-HIV Drug Segment by Type
1.2.1 Global Long-acting Anti-HIV Drug Market Value Comparison by Type (2024-2030)
1.2.2 CAB Long-acting Injection
1.2.3 RPV Long-acting Injection
1.3 Long-acting Anti-HIV Drug Segment by Application
1.3.1 Global Long-acting Anti-HIV Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Long-acting Anti-HIV Drug Market Size Estimates and Forecasts
1.4.1 Global Long-acting Anti-HIV Drug Revenue 2019-2030
1.4.2 Global Long-acting Anti-HIV Drug Sales 2019-2030
1.4.3 Global Long-acting Anti-HIV Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Long-acting Anti-HIV Drug Market Competition by Manufacturers
2.1 Global Long-acting Anti-HIV Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Long-acting Anti-HIV Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Long-acting Anti-HIV Drug Average Price by Manufacturers (2019-2024)
2.4 Global Long-acting Anti-HIV Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Anti-HIV Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Anti-HIV Drug, Product Type & Application
2.7 Long-acting Anti-HIV Drug Market Competitive Situation and Trends
2.7.1 Long-acting Anti-HIV Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Long-acting Anti-HIV Drug Players Market Share by Revenue
2.7.3 Global Long-acting Anti-HIV Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Long-acting Anti-HIV Drug Retrospective Market Scenario by Region
3.1 Global Long-acting Anti-HIV Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Long-acting Anti-HIV Drug Global Long-acting Anti-HIV Drug Sales by Region: 2019-2030
3.2.1 Global Long-acting Anti-HIV Drug Sales by Region: 2019-2024
3.2.2 Global Long-acting Anti-HIV Drug Sales by Region: 2025-2030
3.3 Global Long-acting Anti-HIV Drug Global Long-acting Anti-HIV Drug Revenue by Region: 2019-2030
3.3.1 Global Long-acting Anti-HIV Drug Revenue by Region: 2019-2024
3.3.2 Global Long-acting Anti-HIV Drug Revenue by Region: 2025-2030
3.4 North America Long-acting Anti-HIV Drug Market Facts & Figures by Country
3.4.1 North America Long-acting Anti-HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Long-acting Anti-HIV Drug Sales by Country (2019-2030)
3.4.3 North America Long-acting Anti-HIV Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Anti-HIV Drug Market Facts & Figures by Country
3.5.1 Europe Long-acting Anti-HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Long-acting Anti-HIV Drug Sales by Country (2019-2030)
3.5.3 Europe Long-acting Anti-HIV Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Long-acting Anti-HIV Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Long-acting Anti-HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Long-acting Anti-HIV Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Long-acting Anti-HIV Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Long-acting Anti-HIV Drug Market Facts & Figures by Country
3.7.1 Latin America Long-acting Anti-HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Long-acting Anti-HIV Drug Sales by Country (2019-2030)
3.7.3 Latin America Long-acting Anti-HIV Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Anti-HIV Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Anti-HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Long-acting Anti-HIV Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Long-acting Anti-HIV Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Anti-HIV Drug Sales by Type (2019-2030)
4.1.1 Global Long-acting Anti-HIV Drug Sales by Type (2019-2024)
4.1.2 Global Long-acting Anti-HIV Drug Sales by Type (2025-2030)
4.1.3 Global Long-acting Anti-HIV Drug Sales Market Share by Type (2019-2030)
4.2 Global Long-acting Anti-HIV Drug Revenue by Type (2019-2030)
4.2.1 Global Long-acting Anti-HIV Drug Revenue by Type (2019-2024)
4.2.2 Global Long-acting Anti-HIV Drug Revenue by Type (2025-2030)
4.2.3 Global Long-acting Anti-HIV Drug Revenue Market Share by Type (2019-2030)
4.3 Global Long-acting Anti-HIV Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Long-acting Anti-HIV Drug Sales by Application (2019-2030)
5.1.1 Global Long-acting Anti-HIV Drug Sales by Application (2019-2024)
5.1.2 Global Long-acting Anti-HIV Drug Sales by Application (2025-2030)
5.1.3 Global Long-acting Anti-HIV Drug Sales Market Share by Application (2019-2030)
5.2 Global Long-acting Anti-HIV Drug Revenue by Application (2019-2030)
5.2.1 Global Long-acting Anti-HIV Drug Revenue by Application (2019-2024)
5.2.2 Global Long-acting Anti-HIV Drug Revenue by Application (2025-2030)
5.2.3 Global Long-acting Anti-HIV Drug Revenue Market Share by Application (2019-2030)
5.3 Global Long-acting Anti-HIV Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead
6.1.1 Gilead Corporation Information
6.1.2 Gilead Description and Business Overview
6.1.3 Gilead Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Long-acting Anti-HIV Drug Product Portfolio
6.1.5 Gilead Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Corporation Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 ViiV Healthcare Long-acting Anti-HIV Drug Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Janssen
6.3.1 Janssen Corporation Information
6.3.2 Janssen Description and Business Overview
6.3.3 Janssen Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Janssen Long-acting Anti-HIV Drug Product Portfolio
6.3.5 Janssen Recent Developments/Updates
6.4 Tibotec
6.4.1 Tibotec Corporation Information
6.4.2 Tibotec Description and Business Overview
6.4.3 Tibotec Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Tibotec Long-acting Anti-HIV Drug Product Portfolio
6.4.5 Tibotec Recent Developments/Updates
6.5 Cipla
6.5.1 Cipla Corporation Information
6.5.2 Cipla Description and Business Overview
6.5.3 Cipla Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cipla Long-acting Anti-HIV Drug Product Portfolio
6.5.5 Cipla Recent Developments/Updates
6.6 Frontier Biopharmaceutical (Nanjing) Co., Ltd.
6.6.1 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Corporation Information
6.6.2 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Description and Business Overview
6.6.3 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product Portfolio
6.6.5 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Anti-HIV Drug Industry Chain Analysis
7.2 Long-acting Anti-HIV Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Anti-HIV Drug Production Mode & Process
7.4 Long-acting Anti-HIV Drug Sales and Marketing
7.4.1 Long-acting Anti-HIV Drug Sales Channels
7.4.2 Long-acting Anti-HIV Drug Distributors
7.5 Long-acting Anti-HIV Drug Customers
8 Long-acting Anti-HIV Drug Market Dynamics
8.1 Long-acting Anti-HIV Drug Industry Trends
8.2 Long-acting Anti-HIV Drug Market Drivers
8.3 Long-acting Anti-HIV Drug Market Challenges
8.4 Long-acting Anti-HIV Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Long-acting Anti-HIV Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Long-acting Anti-HIV Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Long-acting Anti-HIV Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Long-acting Anti-HIV Drug Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Long-acting Anti-HIV Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Long-acting Anti-HIV Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Long-acting Anti-HIV Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Long-acting Anti-HIV Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Long-acting Anti-HIV Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Long-acting Anti-HIV Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Long-acting Anti-HIV Drug, Product Type & Application
Table 12. Global Key Manufacturers of Long-acting Anti-HIV Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Long-acting Anti-HIV Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Anti-HIV Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Long-acting Anti-HIV Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Long-acting Anti-HIV Drug Sales by Region (2019-2024) & (K Units)
Table 18. Global Long-acting Anti-HIV Drug Sales Market Share by Region (2019-2024)
Table 19. Global Long-acting Anti-HIV Drug Sales by Region (2025-2030) & (K Units)
Table 20. Global Long-acting Anti-HIV Drug Sales Market Share by Region (2025-2030)
Table 21. Global Long-acting Anti-HIV Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Long-acting Anti-HIV Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Long-acting Anti-HIV Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Long-acting Anti-HIV Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Long-acting Anti-HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Long-acting Anti-HIV Drug Sales by Country (2019-2024) & (K Units)
Table 27. North America Long-acting Anti-HIV Drug Sales by Country (2025-2030) & (K Units)
Table 28. North America Long-acting Anti-HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Long-acting Anti-HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Long-acting Anti-HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Long-acting Anti-HIV Drug Sales by Country (2019-2024) & (K Units)
Table 32. Europe Long-acting Anti-HIV Drug Sales by Country (2025-2030) & (K Units)
Table 33. Europe Long-acting Anti-HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Long-acting Anti-HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Long-acting Anti-HIV Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Long-acting Anti-HIV Drug Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Long-acting Anti-HIV Drug Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Long-acting Anti-HIV Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Long-acting Anti-HIV Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Long-acting Anti-HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Long-acting Anti-HIV Drug Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Long-acting Anti-HIV Drug Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Long-acting Anti-HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Long-acting Anti-HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Long-acting Anti-HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Long-acting Anti-HIV Drug Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Long-acting Anti-HIV Drug Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Long-acting Anti-HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Long-acting Anti-HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Long-acting Anti-HIV Drug Sales (K Units) by Type (2019-2024)
Table 51. Global Long-acting Anti-HIV Drug Sales (K Units) by Type (2025-2030)
Table 52. Global Long-acting Anti-HIV Drug Sales Market Share by Type (2019-2024)
Table 53. Global Long-acting Anti-HIV Drug Sales Market Share by Type (2025-2030)
Table 54. Global Long-acting Anti-HIV Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Long-acting Anti-HIV Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Long-acting Anti-HIV Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Long-acting Anti-HIV Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Type (2019-2024)
Table 59. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Type (2025-2030)
Table 60. Global Long-acting Anti-HIV Drug Sales (K Units) by Application (2019-2024)
Table 61. Global Long-acting Anti-HIV Drug Sales (K Units) by Application (2025-2030)
Table 62. Global Long-acting Anti-HIV Drug Sales Market Share by Application (2019-2024)
Table 63. Global Long-acting Anti-HIV Drug Sales Market Share by Application (2025-2030)
Table 64. Global Long-acting Anti-HIV Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Long-acting Anti-HIV Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Long-acting Anti-HIV Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Long-acting Anti-HIV Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Application (2019-2024)
Table 69. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Application (2025-2030)
Table 70. Gilead Corporation Information
Table 71. Gilead Description and Business Overview
Table 72. Gilead Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Gilead Long-acting Anti-HIV Drug Product
Table 74. Gilead Recent Developments/Updates
Table 75. ViiV Healthcare Corporation Information
Table 76. ViiV Healthcare Description and Business Overview
Table 77. ViiV Healthcare Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. ViiV Healthcare Long-acting Anti-HIV Drug Product
Table 79. ViiV Healthcare Recent Developments/Updates
Table 80. Janssen Corporation Information
Table 81. Janssen Description and Business Overview
Table 82. Janssen Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Janssen Long-acting Anti-HIV Drug Product
Table 84. Janssen Recent Developments/Updates
Table 85. Tibotec Corporation Information
Table 86. Tibotec Description and Business Overview
Table 87. Tibotec Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Tibotec Long-acting Anti-HIV Drug Product
Table 89. Tibotec Recent Developments/Updates
Table 90. Cipla Corporation Information
Table 91. Cipla Description and Business Overview
Table 92. Cipla Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Cipla Long-acting Anti-HIV Drug Product
Table 94. Cipla Recent Developments/Updates
Table 95. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Corporation Information
Table 96. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Description and Business Overview
Table 97. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product
Table 99. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. Long-acting Anti-HIV Drug Distributors List
Table 103. Long-acting Anti-HIV Drug Customers List
Table 104. Long-acting Anti-HIV Drug Market Trends
Table 105. Long-acting Anti-HIV Drug Market Drivers
Table 106. Long-acting Anti-HIV Drug Market Challenges
Table 107. Long-acting Anti-HIV Drug Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Long-acting Anti-HIV Drug
Figure 2. Global Long-acting Anti-HIV Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Long-acting Anti-HIV Drug Market Share by Type in 2023 & 2030
Figure 4. CAB Long-acting Injection Product Picture
Figure 5. RPV Long-acting Injection Product Picture
Figure 6. Global Long-acting Anti-HIV Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Long-acting Anti-HIV Drug Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Long-acting Anti-HIV Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Long-acting Anti-HIV Drug Market Size (2019-2030) & (US$ Million)
Figure 13. Global Long-acting Anti-HIV Drug Sales (2019-2030) & (K Units)
Figure 14. Global Long-acting Anti-HIV Drug Average Price (US$/Unit) & (2019-2030)
Figure 15. Long-acting Anti-HIV Drug Report Years Considered
Figure 16. Long-acting Anti-HIV Drug Sales Share by Manufacturers in 2023
Figure 17. Global Long-acting Anti-HIV Drug Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Long-acting Anti-HIV Drug Players: Market Share by Revenue in 2023
Figure 19. Long-acting Anti-HIV Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Long-acting Anti-HIV Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Long-acting Anti-HIV Drug Sales Market Share by Country (2019-2030)
Figure 22. North America Long-acting Anti-HIV Drug Revenue Market Share by Country (2019-2030)
Figure 23. United States Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Long-acting Anti-HIV Drug Sales Market Share by Country (2019-2030)
Figure 26. Europe Long-acting Anti-HIV Drug Revenue Market Share by Country (2019-2030)
Figure 27. Germany Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Netherlands Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Long-acting Anti-HIV Drug Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Long-acting Anti-HIV Drug Revenue Market Share by Region (2019-2030)
Figure 34. China Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Long-acting Anti-HIV Drug Sales Market Share by Country (2019-2030)
Figure 42. Latin America Long-acting Anti-HIV Drug Revenue Market Share by Country (2019-2030)
Figure 43. Mexico Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Brazil Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Argentina Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Colombia Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Long-acting Anti-HIV Drug Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Long-acting Anti-HIV Drug Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Long-acting Anti-HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Long-acting Anti-HIV Drug by Type (2019-2030)
Figure 53. Global Revenue Market Share of Long-acting Anti-HIV Drug by Type (2019-2030)
Figure 54. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Long-acting Anti-HIV Drug by Application (2019-2030)
Figure 56. Global Revenue Market Share of Long-acting Anti-HIV Drug by Application (2019-2030)
Figure 57. Global Long-acting Anti-HIV Drug Price (US$/Unit) by Application (2019-2030)
Figure 58. Long-acting Anti-HIV Drug Value Chain
Figure 59. Long-acting Anti-HIV Drug Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock